Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients for more than three decades, SCRI is a leader in drug development. We have conducted more than 900 first-in-human clinical trials since our inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade.

In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. SCRI’s research network brings together approximately 1,500 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S.